Cargando…

Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study

The mRNA-based BNT162b2 vaccine has demonstrated high efficacy against severe SARS-CoV-2. However, data regarding immune response in people with diabetes mellitus (DM) after vaccination with the BNT162b2 vaccine are limited. In this prospective observational study, we examined humoral immune respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Papadokostaki, Eleni, Tentolouris, Anastasios, Anastasiou, Ioanna A., Psichogiou, Mina, Iliaki, Evangelia, Eleftheriadou, Ioanna, Hatzakis, Angelos, Tentolouris, Nikolaos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954340/
https://www.ncbi.nlm.nih.gov/pubmed/35335014
http://dx.doi.org/10.3390/vaccines10030382
_version_ 1784676070397575168
author Papadokostaki, Eleni
Tentolouris, Anastasios
Anastasiou, Ioanna A.
Psichogiou, Mina
Iliaki, Evangelia
Eleftheriadou, Ioanna
Hatzakis, Angelos
Tentolouris, Nikolaos
author_facet Papadokostaki, Eleni
Tentolouris, Anastasios
Anastasiou, Ioanna A.
Psichogiou, Mina
Iliaki, Evangelia
Eleftheriadou, Ioanna
Hatzakis, Angelos
Tentolouris, Nikolaos
author_sort Papadokostaki, Eleni
collection PubMed
description The mRNA-based BNT162b2 vaccine has demonstrated high efficacy against severe SARS-CoV-2. However, data regarding immune response in people with diabetes mellitus (DM) after vaccination with the BNT162b2 vaccine are limited. In this prospective observational study, we examined humoral immune response in participants with and without DM after vaccination with the BNT162b2 mRNA vaccine. A total of 174 participants (58 with and 116 without diabetes, matched for age) were included. Antibodies were measured 21 days after the first dose, 7–15 days after the second dose, and 70–75 days after the second and before the third dose of the vaccine. Antibodies were measured by an anti-SARS-CoV-2 receptor-binding domain IgG (Abs-RBD-IgG) assay by a chemiluminescent microparticle immune assay; values > 50 AU/mL are considered protective from severe disease. Almost 17% of participants with DM did not develop adequate humoral immune response to the BNT162b2 mRNA vaccine after the first dose; however, it was high and similar after the second dose in both participants with and without DM and remained so almost 2 months after the second dose of the vaccine. Geometric mean values of Abs-RBD-IgG were not significantly different between participants with and without DM during the study. At least two doses of the BNT162b2 vaccine are necessary to ensure adequate and sustainable immune response in people with DM.
format Online
Article
Text
id pubmed-8954340
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89543402022-03-26 Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study Papadokostaki, Eleni Tentolouris, Anastasios Anastasiou, Ioanna A. Psichogiou, Mina Iliaki, Evangelia Eleftheriadou, Ioanna Hatzakis, Angelos Tentolouris, Nikolaos Vaccines (Basel) Brief Report The mRNA-based BNT162b2 vaccine has demonstrated high efficacy against severe SARS-CoV-2. However, data regarding immune response in people with diabetes mellitus (DM) after vaccination with the BNT162b2 vaccine are limited. In this prospective observational study, we examined humoral immune response in participants with and without DM after vaccination with the BNT162b2 mRNA vaccine. A total of 174 participants (58 with and 116 without diabetes, matched for age) were included. Antibodies were measured 21 days after the first dose, 7–15 days after the second dose, and 70–75 days after the second and before the third dose of the vaccine. Antibodies were measured by an anti-SARS-CoV-2 receptor-binding domain IgG (Abs-RBD-IgG) assay by a chemiluminescent microparticle immune assay; values > 50 AU/mL are considered protective from severe disease. Almost 17% of participants with DM did not develop adequate humoral immune response to the BNT162b2 mRNA vaccine after the first dose; however, it was high and similar after the second dose in both participants with and without DM and remained so almost 2 months after the second dose of the vaccine. Geometric mean values of Abs-RBD-IgG were not significantly different between participants with and without DM during the study. At least two doses of the BNT162b2 vaccine are necessary to ensure adequate and sustainable immune response in people with DM. MDPI 2022-03-02 /pmc/articles/PMC8954340/ /pubmed/35335014 http://dx.doi.org/10.3390/vaccines10030382 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Papadokostaki, Eleni
Tentolouris, Anastasios
Anastasiou, Ioanna A.
Psichogiou, Mina
Iliaki, Evangelia
Eleftheriadou, Ioanna
Hatzakis, Angelos
Tentolouris, Nikolaos
Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study
title Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study
title_full Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study
title_fullStr Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study
title_full_unstemmed Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study
title_short Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study
title_sort immunogenicity of sars-cov-2 bnt162b2 vaccine in people with diabetes: a prospective observational study
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954340/
https://www.ncbi.nlm.nih.gov/pubmed/35335014
http://dx.doi.org/10.3390/vaccines10030382
work_keys_str_mv AT papadokostakieleni immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy
AT tentolourisanastasios immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy
AT anastasiouioannaa immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy
AT psichogioumina immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy
AT iliakievangelia immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy
AT eleftheriadouioanna immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy
AT hatzakisangelos immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy
AT tentolourisnikolaos immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy